| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,540,000 |
| Market
Cap: |
346.61(M) |
| Last
Volume: |
34,905,322 |
Avg
Vol: |
12,269,127 |
| 52
Week Range: |
$4.1 - $4.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Olson William C |
VP, Research & Development |
• – – |
2008-06-23 |
4 |
D |
$17.01 |
$59,546 |
D/D |
(3,500) |
29,678 |
|
- |
|
| Boyd Thomas A |
Sr. VP, Product Dev. |
• – – |
2008-06-23 |
4 |
D |
$17.01 |
$45,914 |
D/D |
(2,700) |
29,205 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-06-23 |
4 |
D |
$17.02 |
$59,553 |
D/D |
(3,500) |
32,791 |
|
- |
|
| Mckinney Robert A |
Chief Financial Officer |
• – – |
2008-06-20 |
4 |
D |
$17.15 |
$79,986 |
D/D |
(4,665) |
29,247 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-06-02 |
4 |
AS |
$16.40 |
$16,397 |
D/D |
(1,000) |
36,291 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-06-02 |
4 |
OE |
$12.29 |
$12,290 |
D/D |
1,000 |
37,291 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-05-27 |
4 |
AS |
$15.00 |
$15,000 |
D/D |
(1,000) |
36,291 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-05-27 |
4 |
OE |
$12.29 |
$12,290 |
D/D |
1,000 |
37,291 |
|
- |
|
| Dalton Mark F |
Director |
– • – |
2008-05-14 |
4 |
OE |
$4.41 |
$40,225 |
D/D |
7,500 |
78,500 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-04-25 |
4 |
AS |
$15.00 |
$15,000 |
D/D |
(1,000) |
36,291 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-04-25 |
4 |
OE |
$12.29 |
$12,290 |
D/D |
1,000 |
37,291 |
|
- |
|
| Kremer Alton B |
VP, Clinical Research |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$22,005 |
D/D |
(2,869) |
25,302 |
|
- |
|
| Kremer Alton B |
VP, Clinical Research |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$20,558 |
D/D |
3,153 |
28,171 |
|
- |
|
| Kremer Alton B |
VP, Clinical Research |
• – – |
2008-04-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,000) |
24,849 |
|
- |
|
| Olson William C |
VP, Research & Development |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$11,006 |
D/D |
(1,435) |
33,178 |
|
- |
|
| Olson William C |
VP, Research & Development |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$10,276 |
D/D |
1,576 |
34,613 |
|
- |
|
| Mckinney Robert A |
Chief Financial Officer |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$13,361 |
D/D |
(1,742) |
33,912 |
|
- |
|
| Mckinney Robert A |
Chief Financial Officer |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$12,479 |
D/D |
1,914 |
35,654 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$18,861 |
D/D |
(2,459) |
36,291 |
|
- |
|
| Israel Robert J |
Sr. VP, Medical Affairs |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$17,617 |
D/D |
2,702 |
38,750 |
|
- |
|
| Boyd Thomas A |
Sr. VP, Product Dev. |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$13,361 |
D/D |
(1,742) |
31,905 |
|
- |
|
| Boyd Thomas A |
Sr. VP, Product Dev. |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$12,479 |
D/D |
1,914 |
33,647 |
|
- |
|
| Boyd Thomas A |
Sr. VP, Product Dev. |
• – – |
2008-04-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,000) |
31,564 |
|
- |
|
| Baker Mark Robert |
General Counsel |
• – – |
2008-04-01 |
4 |
D |
$7.67 |
$17,679 |
D/D |
(2,305) |
25,417 |
|
- |
|
| Baker Mark Robert |
General Counsel |
• – – |
2008-04-01 |
4 |
OE |
$6.52 |
$16,515 |
D/D |
2,533 |
27,722 |
|
- |
|
801 Records found
|
|
Page 12 of 33 |
|
|
